SCHEMBL1271128

SCHEMBL1271128

CCCCC/C=C/C=C\C=C\CCCCCCC(=O)O

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.96
PPARG P37231 5/20 0.81
PPARD Q03181 5/20 0.81
PPARA Q07869 5/20 0.81
F7 P08709 5/20 0.81
F3 P13726 5/20 0.81
TERT O14746 3/20 0.81
PTPN1 P18031 3/20 0.81
HSD17B10 Q99714 3/20 0.81
FABP4 P15090 3/20 0.81
MAPT P10636 2/20 0.81
BLM P54132 2/20 0.81
LMNA P02545 2/20 0.81
ALOX15 P16050 2/20 0.81
DUSP3 P51452 2/20 0.81
CYP19A1 P11511 2/20 0.81
PTGS1 P23219 2/20 0.81
NR4A2 P43354 2/20 0.81
SIRT6 Q8N6T7 2/20 0.81
PTPN7 P35236 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647674 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL2230814 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL1017653 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL23698235 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL37277 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL23698236 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL16994321 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL1647672 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL3399216 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7
SCHEMBL1017655 1.00 FASN (0.96) FASNPPARGPPARDPPARAF7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009032699-A1 ANTI-PROLIFERATIVE COMBINATIONS DRUGTECH CORPORATION (US) 2009-03-12 WO claimed
US-20090068190-A1 ANTI-PROLIFERATIVE COMBINATIONS DRUGTECH CORPORATION (US) 2009-03-12 US claimed
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE Axitan Ltd. (GB) 2026-05-28 US disclosed
US-12471609-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-11-18 US disclosed
US-20250177439-A1 LOW DOSE PRE-MIX FEED FOR TRACE MINERAL SUPPLEMENTATION Chemlock Operating LLC d/b/a Chemlock Nutrition (US) 2025-06-05 US disclosed
US-12310386-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-05-27 US disclosed
US-20250008984-A1 REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED NOVUS INTERNATIONAL, INC. 2025-01-09 US disclosed
US-20230165275-A1 REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED NOVUS INTERNATIONAL, INC. 2023-06-01 US disclosed
US-11564405-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2023-01-31 US disclosed
EP-3328199-B1 ANTIMICROBIAL COMPOSITIONS AND USES THEREOF NOVUS INT INC (US) 2022-03-23 EP disclosed
EP-3934627-A1 REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED Novus International Inc. (US) 2022-01-12 EP disclosed
US-20100297254-A1 NUTRACEUTICAL COMPOSITION AND METHODS OF USE DACY TECH PTY LTD (AU) 2010-11-25 US disclosed
EP-2240190-A1 NUTRACEUTICAL COMPOSITION AND METHODS OF USE Dacy Tech Pty Ltd (AU) 2010-10-20 EP disclosed
WO-2009073931-A1 NUTRACEUTICAL COMPOSITION AND METHODS OF USE DACY TECH PTY LTD (AU) 2009-06-18 WO disclosed
US-20090124574-A1 Carotenoid analogs and derivatives for the prevention of platelet aggregation CARDAX PHARMA, INC. 2009-05-14 US disclosed
US-20090099061-A1 SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS CARDAX PHARMACEUTICALS, INC. 2009-04-16 US disclosed
WO-2009032699-A1 ANTI-PROLIFERATIVE COMBINATIONS DRUGTECH CORPORATION (US) 2009-03-12 WO disclosed
US-20090068190-A1 ANTI-PROLIFERATIVE COMBINATIONS DRUGTECH CORPORATION (US) 2009-03-12 US disclosed
WO-2008118862-A1 CAROTENOID ANALOGS AND DERIVATIVES FOR THE PREVENTION OF PLATELET AGGREGATION CARDAX PHARMACEUTICALS, INC. (US) 2008-10-02 WO disclosed
WO-2008106606-A2 CAROTENOID ANALOGS AND DERIVATIVES IN THE TREATMENT OF PROSTATE CANCER CARDAX PHARMACEUTICALS, INC. (US) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE ELOVL6, CROCC, ELOC FASN 319/4885PPARG 1938/4885PPARD 1774/4885
US-20090068190-A1 ANTI-PROLIFERATIVE COMBINATIONS FOLR2, FOLR1, DHFR FASN 13/4885PPARG 164/4885PPARD 166/4885
US-20090124574-A1 Carotenoid analogs and derivatives for the prevention of platelet aggregation PROC, PFKP, PF4 FASN 1170/4885PPARG 386/4885PPARD 206/4885
US-20090099061-A1 SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS CAT, HBZ, POLL FASN 231/4885PPARG 633/4885PPARD 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.